Saving African Americans & Hispanics diagnosed with COVID-19

Thirty-three million people (33,000,000) have been diagnosed with COVID in the US. Nearly 600,000 people have died. African Americans and Hispanics disproportionately contract and needlessly die from the virus.

 

A clinical, multi-site study is underway of NOi's COVID drug NOviricid, the FIRST Oral Systemic Nitric Oxide-based COVID-19 Drug.  This is the ONLY study specifically addressing the health needs of African Americans and Hispanics with COVID. NOi believes that early intervention with NOviricid will prevent hospitalization, the need for ventilation, and death.

Despite the vaccine and its yet unknown long-term side-effects, duration of efficacy, and effect on mutations, every year people will continue to contract the virus. While the vaccine hopes to prevent the virus, NOviricid seeks to SAVE those infected with COVID-19 and all of its mutations.

Dr Nathan S. Bryan Ph.D.

Founder/Inventor/Researcher

  • The recognized expert and thought leader in nitric oxide
     

  • Innovative and prolific inventor
     

  • More than two dozen issued U.S. and International Patents on nitric oxide technology
     

  • Hundreds of peer-reviewed publications in the nitric oxide field
     

  • His patented technology is responsible for hundreds of millions of dollars in product sales worldwide

Nitric Oxide Based Therapeutics
for Human Disease

NITRIC OXIDE

WOUND CARE

COVID 19

CARDIOVASCULAR

R & D

The Journey Towards Disease & Aging Prevention Begins with

Sufficient Nitric Oxide Production.

"The discovery of nitric oxide and its function is one of the most important in the history of cardiovascular medicine."

- Valentine Fuster, M.D.
1998 President, American Heart Association
Head of Cardiology, Mount Sinai Hospital NYC

The Healthy Feed